Pharmaceutical companies would have to spend a lot of money on pediatric anticoagulation studies for diseases that are rare among these patients, explained Michael A. Portman, MD, FAHA, of Seattle Children's Hospital.
Pharmaceutical companies would have to spend a lot of money on pediatric anticoagulation studies, for diseases that are rare among these patients, and the statistical methods differ as well for adult studies, explained Michael A. Portman, MD, FAHA, director, Pediatric Cardiovascular Research, Center for Integrative Brain Research, and professor of pediatrics at Seattle Children's Hospital and the University of Washington in Seattle.
Transcript
Why have there been few studies on the use of pediatric anticoagulation?
I think it’s most due to the interest [from] the pharmaceutical companies and spending the money. They would have to spend a lot of money on relatively few patients who would take their medications. So for this study, we were really fortunate in that Daiichi Sankyo sponsored the study. We enrolled quite a few patients for a pediatric study; we had, I believe, 168 patients enrolled—so that's pretty large for a pediatric study. In contrast, for an adult study, you would have thousands of patients. So there are difficulties even when the drug company sponsors [a study]; there is a rarity of the patients, because these are rare diseases. And most of the companies and actually the FDA demands certain statistical methods. And you really can't use those statistical methods in children because of the rarity of the diseases. So that's another barrier, the type of information that the FDA requires for approval of those drugs, although I think they're becoming more lenient, understanding that we can't use adult type trial design in children.
Dr Kathryn Lindley on Pregnancy-Related Cardiovascular Care Gaps and Training Initiatives
December 8th 2023Cardiologists need skills in risk assessment, contraception counseling, and hypertension management for pregnant patients, according to Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.
Read More
Study: SGLT2is Should Be Continued Despite Initial eGFR Decline in Patients With HFmrEF/HFpEF
December 6th 2023Despite an initial drop in estimated glomerular filtration rate (eGFR) after 1 month of dapagliflozin, researchers say this is not associated with subsequent risk of cardiovascular or kidney events for patients with heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF).
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen